Shares have risen by 55% since initially presenting the idea to readers.
I recap the bullish thesis and remind readers of the untapped potential for Ingrezza.
The company´s pediatric Tourette syndrome program is progressing nicely despite a clinical ¨hiccup¨.
Management appears to be executing solidly on their game plan considering the so far successful launch of Ingrezza and progression of their pipeline.
Readers who have done their due diligence should purchase a pilot position in the near term and adopt a “buy the dips” approach. Pay close attention to upcoming catalysts and continuing launch metrics.
Shares of Neurocrine Biosciences (NBIX) have risen by 55% since I presented the idea to readers last April stating that the stock had room to run after the FDA approved Ingrezza for the treatment of Tardive Dyskinesia. The stock has also done quite well since my May update piece where I noted that the bullish thesis had been strengthened due to premium pricing established for Ingrezza and a strengthened cash position that would better allow management to execute on their plan or possibly negotiate a better sale price for the company.